Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rigel R&D Strategy Emphasizes Early Pipeline, Led By Asthma Drug

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Rigel’s focus on its early-stage projects for serious unmet medical needs overshadowed its Phase III rheumatoid arthritis candidate with AstraZeneca.

You may also be interested in...



With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results

Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.

Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success

During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.

Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question

Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS004867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel